公开(公告)号：US10251945B2

公开(公告)日：2019-04-09

申请号：US16198387

申请日：2018-11-21

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： John J. Engelhardt ,  Mark J. Selby ,  Alan J. Korman ,  Mary Diane Feingersh ,  Brenda L. Stevens

IPC: C07K16/28 ,  A61K39/395 ,  A61K39/00 ,  A61P35/00

Abstract: The present invention provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies) that bind to human Inducible T Cell COStimulator (ICOS) and exhibit therapeutically desirable functional properties, e.g., the ability to stimulate human ICOS activity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells, and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the antibodies of the invention are also provided. The antibodies of the invention can be used, for example, as an agonist to stimulate or enhance an immune response in a subject, e.g., antigen-specific T cell responses against a tumor or viral antigen. The antibodies of the invention can also be used in combination with other antibodies (e.g., PD-1, PD-L1, and/or CTLA-4 antibodies) to treat, for example, cancer. Accordingly, the antibodies can be used in therapeutic applications and methods to detect ICOS protein.

公开(公告)号：US10898556B2

公开(公告)日：2021-01-26

申请号：US15946625

申请日：2018-04-05

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： John J. Engelhardt ,  Mark J. Selby ,  Alan J. Korman ,  Mary Diane Feingersh ,  Brenda L. Stevens

IPC: C07K16/28 ,  A61K39/395 ,  A61K39/00 ,  A61P35/00

Abstract: The present invention provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies) that bind to human Inducible T Cell COStimulator (ICOS) and exhibit therapeutically desirable functional properties, e.g., the ability to stimulate human ICOS activity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells, and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the antibodies of the invention are also provided. The antibodies of the invention can be used, for example, as an agonist to stimulate or enhance an immune response in a subject, e.g., antigen-specific T cell responses against a tumor or viral antigen. The antibodies of the invention can also be used in combination with other antibodies (e.g., PD-1, PD-L1, and/or CTLA-4 antibodies) to treat, for example, cancer. Accordingly, the antibodies can be used in therapeutic applications and methods to detect ICOS protein.

公开(公告)号：US11207391B2

公开(公告)日：2021-12-28

申请号：US16351995

申请日：2019-03-13

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： John J. Engelhardt ,  Mark J. Selby ,  Alan J. Korman ,  Mary Diane Feingersh ,  Brenda L. Stevens

IPC: C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  A61K39/00

Abstract: The present invention provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies) that bind to human Inducible T Cell COStimulator (ICOS) and exhibit therapeutically desirable functional properties, e.g., the ability to stimulate human ICOS activity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells, and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the antibodies of the invention are also provided. The antibodies of the invention can be used, for example, as an agonist to stimulate or enhance an immune response in a subject, e.g., antigen-specific T cell responses against a tumor or viral antigen. The antibodies of the invention can also be used in combination with other antibodies (e.g., PD-1, PD-L1, and/or CTLA-4 antibodies) to treat, for example, cancer. Accordingly, the antibodies can be used in therapeutic applications and methods to detect ICOS protein.

公开(公告)号：US20190076515A1

公开(公告)日：2019-03-14

申请号：US16198387

申请日：2018-11-21

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： John J. Engelhardt ,  Mark J. Selby ,  Alan J. Korman ,  Mary Diane Feingersh ,  Brenda L. Stevens

IPC: A61K39/00 ,  C07K16/28 ,  A61K39/395 ,  A61P35/00

Abstract: The present invention provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies) that bind to human Inducible T Cell COStimulator (ICOS) and exhibit therapeutically desirable functional properties, e.g., the ability to stimulate human ICOS activity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells, and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the antibodies of the invention are also provided. The antibodies of the invention can be used, for example, as an agonist to stimulate or enhance an immune response in a subject, e.g., antigen-specific T cell responses against a tumor or viral antigen. The antibodies of the invention can also be used in combination with other antibodies (e.g., PD-1, PD-L1, and/or CTLA-4 antibodies) to treat, for example, cancer. Accordingly, the antibodies can be used in therapeutic applications and methods to detect ICOS protein.

公开(公告)号：US11529399B2

公开(公告)日：2022-12-20

申请号：US16601231

申请日：2019-10-14

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： John J. Engelhardt ,  Mark J. Selby ,  Alan J. Korman ,  Mary Diane Feingersh ,  Brenda L. Stevens

IPC: C07K16/28 ,  A61K39/395 ,  A61K39/00 ,  A61P35/00

Abstract: The present invention provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies) that bind to human Inducible T Cell COStimulator (ICOS) and exhibit therapeutically desirable functional properties, e.g., the ability to stimulate human ICOS activity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells, and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the antibodies of the invention are also provided. The antibodies of the invention can be used, for example, as an agonist to stimulate or enhance an immune response in a subject, e.g., antigen-specific T cell responses against a tumor or viral antigen. The antibodies of the invention can also be used in combination with other antibodies (e.g., PD-1, PD-L1, and/or CTLA-4 antibodies) to treat, for example, cancer. Accordingly, the antibodies can be used in therapeutic applications and methods to detect ICOS protein.

公开(公告)号：US20190175705A1

公开(公告)日：2019-06-13

申请号：US16281447

申请日：2019-02-21

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： John J. Engelhardt ,  Mark J. Selby ,  Alan J. Korman ,  Mary Diane Feingersh ,  Brenda L. Stevens

IPC: A61K39/00 ,  A61K39/395 ,  C07K16/28 ,  A61P35/00

Abstract: The present invention provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies) that bind to human Inducible T Cell COStimulator (ICOS) and exhibit therapeutically desirable functional properties, e.g., the ability to stimulate human ICOS activity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells, and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the antibodies of the invention are also provided. The antibodies of the invention can be used, for example, as an agonist to stimulate or enhance an immune response in a subject, e.g., antigen-specific T cell responses against a tumor or viral antigen. The antibodies of the invention can also be used in combination with other antibodies (e.g., PD-1, PD-L1, and/or CTLA-4 antibodies) to treat, for example, cancer. Accordingly, the antibodies can be used in therapeutic applications and methods to detect ICOS protein.